ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat's Phase IIb Trial in Borderline Personality Disorder

Stock Information for Blueknight Energy Partners L.P.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Blueknight Energy Partners L.P.

Orion Group Holdings Reports First Quarter 2024 Results
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
Orion Group Holdings, Inc. to Report First Quarter 2024 Financial Results on Wednesday, April 24
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
ORYZON to Provide Corporate Progress Updates at Several Events in April
Orion Group Holdings, Inc. Announces Retirement of Board Member
Orion Group Holdings Reports Fourth Quarter and Full Year 2023 Results
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.